国际循环网版权所有，谢绝任何形式转载，侵犯版权者必予法律追究。

International Circulation: Last October， you published an article entitled， “The SIRIUS-DIRECT Trial: A Multi-Center Study of Direct Stenting Using the Sirolimus-Eluting Stent in Patients with De Novo Native Coronary Artery Lesions” in Catheter Cardiovascular Intervention. Results showed that direct stenting using sirolimus-eluting stents achieves excellent short and long-term clinical and angiographic results with shorter procedure time and less frequent stent edge restenosis compared with predilitation stent implantation techniques. Could you explain the main reason for the difference? Professor Moses: I think there are two aspects， which have also been verified by other studies. Obviously， the shortened procedure time is because of the lack of predilitation. It’s been well-demonstrated， even with bare metal stenting， that resource use goes down when you do direct stenting. That wasn’t a surprise， but others have also observed that longitudinal geographic miss with drug-eluting stents， especially Cypher， can lead to MACE events， especially restenosis. By definition here， if you do not predilate and you just implant the stent directly， that virtually eliminates the longitudinal miss， and I think that accounted for the outcomes that were particularly noticeably better in diabetics when compared to the original SIRIUS data set.